At Boston Atrial Fibrillation Symposium 2010, Prof. John Camm talked about the two newest antiarrhythmic drugs for atrial fibrillation treatment, dronedarone (Multaq®) and vernakalant. These antiarrhythmic (rhythm control) drugs help to put patients back into normal sinus rhythm, or to keep them in it. See the video: Interview with Professor John Camm at Boston Atrial …
Read More
If you have a problem getting Medicare, Medicare Advantage, or your health insurance plan to cover an atrial fibrillation treatment, such as an afib medication, catheter ablation, or mini maze surgery, you don’t have to take "no" for an answer. You can push back by requesting a "coverage determination" or submitting an appeal. To learn …
Read More
Urgent coordinated action is needed to avoid the thousands of preventable strokes that leave many atrial fibrillation (AF) patients mentally and physically disabled or dead every year. A report, How Can We Avoid a Stroke Crisis?, was launched today in the European Parliament in Brussels by Action for Stroke Prevention, a group of health experts …
Read More
This very important story may change how afib patients and their doctors decide if they should be on anticoagulant medications (blood thinners), such as Coumadin or warfarin. The CHADS2 scoring system is how doctors now decide who should be on Coumadin or warfarin to avoid strokes, but a newly-published study adds new stroke risk factors …
Read More
RECORD AF registry findings were presented at the American Heart Association Scientific Sessions. This registry looked at how newly-diagnosed afib patients were being managed in the real world. These results differed from previously-reported research, such as the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) trial. In the real world, more cardiologists chose rhythm drugs …
Read More
The Agency for Healthcare Research and Quality (AHRQ) has introduced a video to help those on anticoagulant drugs, such as Coumadin or warfarin, to use them safely. The video is designed to complement what patients learn from their doctors, pharmacies, or Coumadin clinics. Anticoagulants reduce the risk of stroke in those with atrial fibrillation by …
Read More
If you're interested in being part of a clinical research study comparing an investigational drug (a drug that is not FDA-approved) to Coumadin®, please contact: Jay Garcia Novellus Research Sites 11160 Warner Ave, Suite 109 Fountain Valley, CA 92708 714-786-5155
Read More
There is a lot of big news coming out of the European Society of Cardiology (ESC) going on in Barcelona right now. Judging by attendance, this is probably the biggest cardiology event in the world. The big announcement for atrial fibrillation sufferers is the progress towards a replacement for Coumadin (warfarin) coming out of the …
Read More
We hear from so many afib patients every day about the trials, tribulations, and fears regarding being on amiodarone, or their refusal to take it. Since the FDA approved Multaq® (dronedarone) recently, the most frequent question I've fielded has been "When will Multaq® be available?" That happened this week, and the excitement they have shared …
Read More
BREAKING NEWS Multaq(R), the much anticipated replacement for amiodarone, just received FDA approval. Read the press release: FDA Approves Multaq® for Patients with Atrial Fibrillation or Atrial Flutter
Read More